前舒安胶囊治疗Ⅲ型前列腺炎的临床研究  被引量:2

Clinical research of treating type Ⅲ prostatitis with Qianshu'an capsule

在线阅读下载全文

作  者:孙哲[1] 胡海翔[1] 徐少强[1] 韦仕福 马春晓[2] 

机构地区:[1]中国人民解放军空军总医院中西医结合男科,北京100142 [2]北京中医药大学东直门医院,北京100029

出  处:《中国性科学》2017年第10期13-15,共3页Chinese Journal of Human Sexuality

基  金:2016年度军队后勤科研计划项目(BKJ16J010);2016年度军队计生专业科研课题项目(16JS004)

摘  要:目的:探讨前舒安胶囊治疗Ⅲ型前列腺炎的临床疗效。方法:试验采用自身对照试验,共纳入73例受试者,治疗周期共4周,分别于治疗前、治疗后第2周、治疗后第4周进行NIH-CPSI评分及前列腺按摩液ESP中白细胞计数,并评估疗效。结果:纳入试验病例共71例,4周治疗后,治愈5例(7.0%)显效23例(32.4%),有效32例(45.1%),无效11例(15.5%),总有效率为84.5%;治疗第2周、第4周NIHCPSI评分比较治疗前NIH-CPSI总评分、排尿质量评分、生活质量评分均有显著统计学差异(P<0.01);治疗第2周、第4周与治疗前相比,EPS中WBC计数均有统计学差异(P<0.05)。治疗期间未观察到不良反应事件。结论:采用前舒安胶囊治疗Ⅲ型前列腺炎疗效确切,安全性高,能够显著改善患者疼痛症状,提高生活质量。Objectives: To investigate the clinical curative effect of Qianshu'an capsule in treating type Ⅲprostatitis. Methods: The NIH-CPSI score and the WBC count in the prostate massage fluid ESP were measured before treatment,at 2 weeks after treatment and at 4 weeks after the treatment among the 73 subjects treated in theself-controlled trials. The efficacy was evaluated. Results: At 4 weeks after the treatment,there were 5 cases(7. 0%) cured,23 cases(32. 4%) remarkably effective,32 cases(45. 1%) effective and 11 cases(15. 5%) ineffective,a total effective rate of 84. 5%. Differences in the NIH-CPSI score,the voiding quality score and the quality of life score of NIH-CPSI between before and 2 weeks and 4 weeks after treatment were significantly different( P 0. 01). Difference in the WBC count in EPS was significantly different between before and 2 weeks and 4 weeks after treatment( P 0. 05). No adverse events were observed during treatment. Conclusion: Qianshu'an capsule is effective and safe in treating patients with type Ⅲ prostatitis,which can significantly improve the pain symptoms and improve the quality of life.

关 键 词:前舒安胶囊 Ⅲ型前列腺炎 慢性前列腺炎症状评分 生活质量 

分 类 号:R697.33[医药卫生—泌尿科学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象